CC531 Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Tumor Cells |
| Tissue Type |
Rat cell lines |
| Organism |
Rat |
| Donor History |
Adenocarcinoma |
| Growth Properties |
Adherent |
| Growth Conditions |
Culture medium: RPMI 1640 ,w: 2.0 mM stable Glutamine ,w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS ,20 mM HEPES. Dissociation reagent: Accutase. Seeding density: 1 to 2 x 10⁴ cells/cm² will result in a confluent monolayer within 3 to 4 days. Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
CC531 is a well-characterized rat adenocarcinoma cell line derived from the colon. It was originally established from a chemically induced colon tumor in a Wistar rat using 1,2-dimethylhydrazine (DMH), a potent carcinogen. The CC531 cell line is commonly utilized as a model system to study colorectal cancer mechanisms and the tumor microenvironment in vivo, particularly within the context of metastasis and immune responses. These cells are immunogenic and are often used in syngeneic rat models to investigate the efficacy of cancer immunotherapies and the interaction between cancer cells and the immune system.
In research settings, CC531 cells are employed to examine the biological processes of colorectal cancer progression, including cell proliferation, apoptosis, and metastatic behavior. The cell line has been instrumental in studying the response of colorectal cancer to various chemotherapeutic agents and radiation therapy, providing insights into the mechanisms of resistance and sensitivity to cancer treatments. Moreover, the CC531 model serves as a valuable tool for the development and optimization of novel therapeutic strategies targeting colorectal cancer, making it crucial for translational cancer research.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

